Guggenheim Reiterates Buy Rating on BillionToOne, Inc.
Guggenheim maintains its buy rating for BillionToOne with a $125 price target, a 4.18% upside from the current price.
Key Points
- On June 29, 2026, Guggenheim reiterated its buy rating for BillionToOne, Inc. (BLLN) with a price target of $125.
- Guggenheim's $125 price target implies 4.18% upside from BillionToOne, Inc.'s ($BLLN) current $119.98 share price.
- BillionToOne shares traded near $119.98 on Wednesday, with a market cap of about $5.52 billion and a forward P/E of 116.5.
- Emerald Advisers, LLC increased its holdings in BillionToOne by 50,613 shares, now holding 239,562 shares valued at $18.91 million.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Guggenheim reiterated its buy rating on BillionToOne, Inc. (NASDAQGS: BLLN) on June 29, 2026, setting a price target of $125. The analyst, Subbu Nambi, continues to view the stock favorably.
Other Institutional Activity in BillionToOne
Emerald Advisers, LLC grew its holdings by 50,613 shares, ending with 239,562 shares worth about $18.91 million. Ameriprise Financial Inc added 97,762 shares, now holding 220,035 shares valued at $17.37 million. Next Century Growth Investors LLC increased its stake by 53,905 shares to 90,564 shares, valued at $7.15 million. Meanwhile, Lord, Abbett & Co. LLC slightly trimmed its position by 2,019 shares, maintaining 44,289 shares worth $3.50 million.
BillionToOne, Inc. Stock Up 28.7%
Shares of NasdaqGS:BLLN traded near $119.98 on Wednesday. BillionToOne, Inc. has a market cap of about $5.52 billion and a P/E ratio of 222.2. Its forward P/E is 116.5, and the stock has a beta of 1.3. The 52-week low is $61.96, and the high is $138.70, with moving averages of $92.58 (50-day) and $89.92 (200-day). The company maintains a strong liquidity position with a current ratio of 10.92 and a quick ratio of 10.48.
$BLLN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
BillionToOne reported revenue of approximately $354.54 million, showing a growth rate of 83.8%. The company achieved a net margin of 7% and a return on equity of 8.7%. Earnings per share stood at $0.54. The next earnings report is expected on August 5, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target cuts vs 0 raises.
-
EPS & revenue
EPS beat estimates by 598.2%. Revenue beat estimates by 9.7%.
-
Profit surprise
EBITDA beat sharply. Operating income beat sharply.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
2 target cuts.
-
Earnings quality
Gross margin up 8.6 points. Operating margin up 20.4 points.
Earnings Call Summary
BillionToOne delivered a standout quarter with 108.4 million dollars in revenue, up 84 percent year over year, while achieving 16 percent operating profit margin and 24 percent adjusted EBITDA margin. Prenatal revenue hit 97.7 million dollars, up 72 percent, and oncology revenue nearly quintupled to 10.7 million dollars. The company launched Unity Confirm, a first noninvasive fetal cell confirmation test, and signed landmark payer contracts with Anthem and United, now covering 300 million lives. Gross margins expanded to 73 percent, up 9 percentage points year over year, driven by higher pricing per test and lower production costs despite growing oncology volume.
Guidance Management raised 2026 total revenue guidance to 445 to 465 million dollars, up 20 million dollars from prior March guidance. They expect 48 to 52 percent growth versus 2025 results. The raise reflects strong Q1 performance and new payer contracts expected to boost pricing per test over the rest of the year.
Negative report. Results or guidance disappointed and expectations are likely to move lower.
Analysts Set New Price Targets
On June 29, 2026, Guggenheim reiterated its buy rating with a $125 price target. Previously, JP Morgan and BTIG maintained their buy ratings with targets of $125 and $130, respectively, on May 7, 2026. Overall, the consensus among seven analysts is a buy rating with a mean price target of $117.71.
About BillionToOne, Inc.
BillionToOne, Inc. is a healthcare company based in Menlo Park, California. It specializes in precision diagnostics, using molecular counting technology to enhance disease detection. Its products include UNITY Complete, a prenatal screening test, and Northstar Select, a liquid biopsy test for cancer mutation detection. The company was founded in 2016 and is led by CEO Dr. Oguzhan Atay.
Bottom Line
Guggenheim's reiterated buy rating and $125 price target suggest continued confidence in BillionToOne's growth prospects. Investors keep a close watch on such analyst updates to gauge market sentiment. As always with 13F filings, remember these insights reflect past positions and may not indicate current holdings.
Get BillionToOne, Inc. alerts
New 13F filings, insider trades, and analyst moves on $BLLN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.